An altered mental status presents a diagnostic challenge for many clinicians. Described here is a case of primary hyperparathyroidism not initially suspected until after a thorough neurological and infectious cause were excluded. A 60-year-old woman presented with altered mental status and gait instability. Her family noticed progressive gait instability and mood swings for the past 4 months. Initial imaging and laboratory values were unable to explain her symptoms. On transfer out of the intensive care unit, her corrected calcium was found to be 13.3 mg/dL with an elevated parathyroid hormone. Her hypercalcaemia was refractory to medical management. Ultrasound found a 2 cm nodule, which was surgically removed and found to be a parathyroid adenoma. Her calcium normalised and neurological deficits subsided. Hypercalcaemia can lead to a constellation of symptoms that include the classical 'stones, bones, abdominal moans and psychic groans' and electrolyte derangements should be considered in the differential of altered mental status.
It’s not always osteoporosis: FGF-23 induced osteomalacia. Introduction Osteomalacia is a bone disorder that is caused by many conditions which could be inherited or acquired, associated with frequent fractures and pain. Tumor induced osteomalacia (TIO) is caused by excess FGF-23 most commonly by mesenchymal tumors, which leads to phosphaturia and inactivation of 1,25 (OH) 2 D 3 , in turn causing chronic pain and/or severe muscle weakness. The diagnoses for these patients is typically delayed by years and many times labelled as osteoporosis. Case Presentation This is a 83 yo African-American male with history of prostate cancer with prostatectomy in 2002 and osteoporosis diagnosed in August 2016 at which time he was started on alendronate, cholecalciferol, and calcium. Since 2013 he had an elevated alkaline phosphatase, and given this oncology was consulted in November 2016 due to history of prostate cancer and metastatic work up. A bone scan performed in November 2016 showed increase uptake in the ribs concerning for metastatic disease, which were not seen in CT of the chest, and PET scan was negative for malignancy. In January 2018, on follow up clinic visit, he was reporting severe bilateral lower extremity weakness and pain causing difficulty walking, progressively getting worse to the point of requiring a wheelchair for about 6-12 months, due to this he was admitted to the hospital for evaluation in February 2018. His phosphorus level was 0.7, and 1,25 (OH) 2 D 3 was also low, suggestive of tumor induced osteomalacia. An FGF-23 level was sent, which was elevated at 456 RU/ml (44-215). On clinic follow up, full physical exam revealed a left chest mass that was 3-4 cm, ovoid, non-tender, mobile and indurated. Patient then stated it had been present for 2-3 years. He underwent excision of the mass in March 2018 which was consistent with osteoclast-like giant cell. Follow up FGF 23 level was 44 (44-215). After the surgery the Patient’s pain resolved, he regained his muscle strength and was able to ambulate without assistance. Conclusion TIO is a rare paraneoplastic syndrome which requires a good level of suspicion. Many patient are treated as osteoporosis erroneously and the actual cause of the disease goes unnoticed for many years. Should be suspected in patients with phosphaturia, low 1,25 (OH) 2 D 3 , and clinical symptoms of muscle weakness and pain. Many times finding this tumors can be challenging and detailed physical exam is important to make the diagnosis. References 1. Florenzano P, Gafni RI, Collins MT. Tumor-induced osteomalacia. Bone Rep. 2017 Sep 20;7:90-97. doi: 10.1016/j.bonr.2017.09.002. eCollection 2017 Dec. 2. Fukumoto S. Physiological regulation and disorders of phosphate metabolism--pivotal role of fibroblast growth factor 23. Intern Med. 2008;47(5...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.